The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 01, 2009
Filed:
Aug. 29, 2007
Stephan Fischer, Polling, DE;
Friederike Hesse, Munich, DE;
Hendrik Knoetgen, Penzberg, DE;
Kurt Lang, Penzberg, DE;
Friedrich Metzger, Freiburg, DE;
Joerg Thomas Regula, Munich, DE;
Christian Schantz, Munich, DE;
Andreas Schaubmar, Penzberg, DE;
Hans-joachim Schoenfeld, Freiburg, DE;
Stephan Fischer, Polling, DE;
Friederike Hesse, Munich, DE;
Hendrik Knoetgen, Penzberg, DE;
Kurt Lang, Penzberg, DE;
Friedrich Metzger, Freiburg, DE;
Joerg Thomas Regula, Munich, DE;
Christian Schantz, Munich, DE;
Andreas Schaubmar, Penzberg, DE;
Hans-Joachim Schoenfeld, Freiburg, DE;
Hoffmann-La Roche Inc., Nutley, NJ (US);
Abstract
The present invention relates to a fusion protein comprising IGF-I or an IGF-I variant N-terminally linked to the C-terminus of a propeptide. The invention relates also to a method involving the use of the aforementioned fusion protein in the production of a lysine-PEGylated IGF-I or IGF-I variant. The method comprises the steps of cultivating a prokaryotic host cell comprising an expression vector containing a nucleic acid encoding the fusion protein and causing the cell to express the fusion protein, recovering and PEGylating said fusion protein, cleaving said PEGylated fusion protein with IgA protease, and recovering lysine-PEGylated IGF-I or IGF-I variant. The invention relates also to a lysine-PEGylated IGF-I or IGF-I variant produced using the above method. In addition, the invention relates to a method for treating a neurodegenerative disorders like Alzheimer's Disease using the lysine-PEGylated IGF-I or IGF-I variant and a composition comprising the lysine-PEGylated IGF-I or IGF-I variant.